[1. Vichyanond P, Kaewsomboon S, Ruangrak S, Visitsunthorn N, Cherdjirapong V, Pongsamart G, et al. Increasing prevalence of allergic diseases among Thai children: The ISAAC III results. J Allergy Clin Immunol. 2003; 111 (Suppl 2):S310.10.1016/S0091-6749(03)81124-7]Search in Google Scholar
[2. Trakultivakorn M, Sangsupawanich P, Vichyanond P. Time trends of the prevalence of asthma, rhinitis and eczema in Thai children-ISAAC (International Study of Asthma and Allergies in Childhood) phase three. J Asthma. 2007; 44:609-11.10.1080/0277090070154011917943570]Open DOISearch in Google Scholar
[3. Vichyanond P, Jirapongsananuruk O, Visitsuntorn N, Tuchinda M. Prevalence of asthma, rhinitis and eczema in children from the Bangkok area using the ISAAC (International Study for Asthma and Allergy in Children) questionnaires. J Med Assoc Thai. 1998; 81: 175-84.]Search in Google Scholar
[4. Teeratakulpisarn J, Pairojkul S, Heng S. Survey of the prevalence of asthma, allergic rhinitis and eczema in schoolchildren from Khon Kaen, Northeast Thailand. an ISAAC study. International Study of Asthma and Allergies in Childhood. Asian Pac J Allergy Immunol. 2000; 18:187-94.]Search in Google Scholar
[5. Dejsomritrutai W, Nana A, Chierakul N, Tscheiguna J, Sompradeekul S, Rattanaumpawan P, et al. Prevalence of bronchial hyperresponsiveness and asthma in the adult population in Thailand. Chest. 2006; 129:602-9.10.1378/chest.129.3.60216537857]Search in Google Scholar
[6. Boonsawat W, Charoenphan P. Prevalence of asthma symptoms in adult in 4 cities of Thailand. Presented at Joint Scientific Meeting of Thoracic Soc Thailand, Malaysia Thoracic Soc and the Singapore Thoracic Soc. Bangkok, 2002, Bangkok.]Search in Google Scholar
[7. Boonsawat W, Charoenphan P, Kiatboonsri S, Wongtim S, Viriyachaiyo V, Photirat C, et al. Survey of asthma control in Thailand. Respirology. 2004; 9:373-8.10.1111/j.1440-1843.2004.00584.x15363011]Open DOISearch in Google Scholar
[8. Briggs AH, Bousquet J, Wallace MV, Busse WW, Clark TJH, Pedersen SE, et al. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy. 2006; 61:531-6.10.1111/j.1398-9995.2006.01038.x16629780]Search in Google Scholar
[9. de Asis ML, Greene R. A cost-effectiveness analysis of a peak flow-based asthma education and selfmanagement plan in a high-cost population. J Asthma. 2004; 41:559-65.10.1081/JAS-120037657]Search in Google Scholar
[10. Ericsson K, Bantje TA, Huber RM, Borg S, Bateman ED. Cost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderatepersistent asthma. Respir Med. 2006; 100:586-94.10.1016/j.rmed.2005.09.03216274980]Search in Google Scholar
[11. Franco R, Santos AC, do Nascimento HF, Souza- Machado C, Ponte E, Souza-Machado A, et al. Costeffectiveness analysis of a state funded program for control of severe asthma. BMC Public Health. 2007; 7:82.10.1186/1471-2458-7-82189615917509137]Search in Google Scholar
[12. Lord J, Ducharme FM, Stamp RJ, Littlejohns P, Churchill R. Cost effectiveness analysis of inhaled anticholinergics for acute childhood and adolescent asthma. BMJ. 1999; 319:1470-1.10.1136/bmj.319.7223.14702829210582930]Search in Google Scholar
[13. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderateto- severe allergic asthma. J Allergy Clin Immunol. 2004; 114:265-9.10.1016/j.jaci.2004.05.04915316501]Search in Google Scholar
[14. Persson U, Ghatnekar O. Cost-effectiveness analysis of inhaled corticosteroids in asthma: a review of the analytical standards. Respir Med. 2003; 97:1-11.10.1053/rmed.2002.140512556004]Search in Google Scholar
[15. Pinnock H, McKenzie L, Price D, Sheikh A. Costeffectiveness of telephone or surgery asthma reviews: economic analysis of a randomised controlled trial. Br J Gen Pract. 2005; 55:119-24.]Search in Google Scholar
[16. Shih YC, Mauskopf J, Borker R. A cost-effectiveness analysis of first-line controller therapies for persistent asthma. Pharmacoeconomics. 2007; 25:577-90.10.2165/00019053-200725070-0000417610338]Open DOISearch in Google Scholar
[17. Sullivan SD, Buxton M, Andersson LF, Lamm CJ, Liljas B, Chen YZ, et al. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol. 2003; 112:1229-36.10.1016/j.jaci.2003.09.02514657888]Search in Google Scholar
[18. Chuesakoolvanich K. Cost of hospitalizing asthma patients in a regional hospital in Thailand. Respirology 2007; 12:433-8.10.1111/j.1440-1843.2007.01032.x17539851]Search in Google Scholar
[19. Visitsunthorn N, Durongpisitkul W, Uoonpan S, Jirapongsananuruk O, Vichyanond P. Medical charge of asthma care in admitted Thai children. J Med Assoc Thai. 2005; 88 (Suppl 8):S16-20.]Search in Google Scholar
[20. O’Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005; 171:129-36.10.1164/rccm.200407-884OC15502112]Search in Google Scholar
[21. Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martinez-Jimenez NE, et al. Effect of budesonide/ formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract. 2007; 61:725-36.10.1111/j.1742-1241.2007.01338.x192054717362472]Open DOISearch in Google Scholar
[22. Edejer TT-T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, et al. editors. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: WHO 2003.]Search in Google Scholar
[23. Cook JR, Drummond M, Glick H, Heyse JF. Assessing the appropriateness of combining economic data from multinational clinical trials. Stat Med. 2003; 22: 1955-76.10.1002/sim.138912802815]Search in Google Scholar
[24. Karlsson G, Johannesson M. The decision rules of costeffectiveness analysis. Pharmacoeconomics. 1996; 9: 113-20.10.2165/00019053-199609020-0000310160090]Open DOISearch in Google Scholar
[25. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York:Chapman & Hall; 1993.10.1007/978-1-4899-4541-9]Search in Google Scholar
[26. Estimated population for Thai Kingdom.20528107]Search in Google Scholar
[27. Boonsawat W, Charoenphan P, Kiatboonsri S. Prevalence of asthma and rhinitis symptoms in adult in 4 cities of Thailand. Presented at 4th World Asthma Meeting, Bangkok, 2004.]Search in Google Scholar
[28. Brouwer W, Rutten F, Koopmanschap M. Costing in economic evaluations. In: Economic evaluation in health care - merging theory with practice. Drummond M, McGuire A, editors. New York: Oxford University Press; 2001.]Search in Google Scholar
[29. Cooper N, Coyle D, Abrams K, Mugford M, Sutton A. Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997. J Health Serv Res Policy. 2005; 10:245-50.10.1258/13558190577441418716259692]Search in Google Scholar
[30. Price D, Wiren A, Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy. 2007; 62:1189-98.10.1111/j.1398-9995.2007.01466.x17845590]Search in Google Scholar
[31. Chapman KR. Seretide for obstructive lung disease. Expert Opin Pharmacother. 2002; 3:341-50.10.1517/14656566.3.3.34111866683]Search in Google Scholar
[32. Main C, Shepherd J, Anderson R, Rogers G, Thompson- Coon J, Liu Z, et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with longacting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years. Health Technol Assess. 2008; 12:1-174.10.3310/hta1220018485272]Search in Google Scholar
[33. Shepherd J, Rogers G, Anderson R, Main C, Thompson- Coon J, Hartwell D, et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Health Technol Assess. 2008; 12:1-254.10.3310/hta1219018485271]Search in Google Scholar